Filing Details
- Accession Number:
- 0001209191-24-000902
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-01-04 19:04:43
- Reporting Period:
- 2024-01-02
- Accepted Time:
- 2024-01-04 19:04:43
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1029142 | Dynavax Technologies Corp | DVAX | Pharmaceutical Preparations (2834) | 330728374 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1573072 | F David Novack | C/O Dynavax Technologies 2100 Powell Street, Suite 720 Emeryville CA 94608 | President & Coo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-01-02 | 9,000 | $5.42 | 12,187 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-01-02 | 9,000 | $14.45 | 3,187 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2024-01-02 | 9,000 | $0.00 | 9,000 | $5.42 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2027-02-11 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on May 5, 2023.
- This transaction was executed in multiple trades at prices ranging from $13.98 to $14.53; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.
- This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 12, 2020, and one thirty-sixth (1/36) of the shares subject to the option vesting on the last day of each month thereafter.
- Not applicable.